Idrossicarbamide Aurobindo

Hydroxycarbamide, the active ingredient in Idrossicarbamide Aurobindo, is a ribonucleotide reductase inhibitor presented as an oral formulation for oral use. It treats chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, sickle cell disease and melanoma in appropriate patients.

GNH USA supplies Idrossicarbamide Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Hydroxycarbamide is employed in hematologic malignancies and selected solid tumours, acting on abnormal cell proliferation.

- Chronic myelogenous leukemia: reduces leukemic cell burden and slows disease progression. - Polycythemia vera: controls excessive red blood cell production and lowers thrombotic risk. - Essential thrombocythemia: decreases platelet counts and mitigates clotting complications. - Sickle cell disease: raises fetal haemoglobin levels, reducing painful vaso‑occlusive crises. - Melanoma: used as adjunct therapy to limit tumour growth.

Hydroxycarbamide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea and vomiting - Diarrhoea - Skin hyperpigmentation - Alopecia (hair loss) - Mild bone‑marrow suppression (e.g., anemia, leukopenia) - Fatigue

Serious or Rare Side Effects: - Severe pancytopenia - Acute renal toxicity - Hepatic dysfunction - Stevens‑Johnson syndrome or other severe cutaneous reactions - Leg ulcers - Secondary malignancies (e.g., acute leukaemia)

Before initiating therapy, clinicians should consider several safety measures.

- Monitor blood counts: perform regular complete blood counts to detect cytopenias. - Assess renal function: adjust dosing in patients with impaired kidney function. - Evaluate hepatic function: monitor liver enzymes during treatment. - Pregnancy risk: contraindicated in pregnancy (Category D) and requires effective contraception. - Contraception advice: both male and female patients should use reliable birth control methods. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture.

Hydroxycarbamide can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Concurrent myelosuppressive agents (e.g., azacitidine, chemotherapy): may cause profound bone‑marrow suppression. - Live vaccines: increased risk of infection due to immunosuppression. - High‑dose aspirin or other antiplatelet drugs: heightened bleeding risk.

Moderate Interactions (Monitor Closely): - NSAIDs: may exacerbate gastrointestinal irritation. - Phenytoin: may reduce hydroxycarbamide plasma concentrations. - Allopurinol: can increase hydroxycarbamide levels, requiring dose adjustment.